Katelyn Daniels։ Final Results of Venetoclax Combination Therapy in Relapsed or Refractory AML
Katelyn Daniels, Physician Scientist Instructor at St. Jude Children’s Research Hospital, shared a post on LinkedIn: “Excited to share our latest publication in The Lancet Haematology reporting the…
Read the full articleYou might also wanna read
Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
Conditions : Chronic Lymphoid Leukemia Interventions : Procedure: Cervical, Thoracic, Abdominal, and Pelvic CT Scan Sponsors : Private Hospi
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
Conditions : Mantle Cell Lymphoma (MCL) Interventions : Drug: Lisaftoclax; Drug: Pirtobrutinib Sponsors : Henan Cancer Hospital Not yet recr
Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse
Conditions : Acute Myeloid Leukemia (AML); Maintenance Treatment; Hematopoetic Stem Cell Transplantation Interventions : Drug: Lisaftoclax P
Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly a
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
Conditions : Chronic Lymphocytic Leukemia Interventions : Drug: Nemtabrutinib; Drug: Venetoclax; Drug: Obinutuzumab Sponsors : Medical Colle
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊
Comments
Sign in to join the conversation.
No comments yet. Be the first.